BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 33658782)

  • 1. Advances in Multiple Stimuli-Responsive Drug-Delivery Systems for Cancer Therapy.
    Jia R; Teng L; Gao L; Su T; Fu L; Qiu Z; Bi Y
    Int J Nanomedicine; 2021; 16():1525-1551. PubMed ID: 33658782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment.
    Chen B; Dai W; He B; Zhang H; Wang X; Wang Y; Zhang Q
    Theranostics; 2017; 7(3):538-558. PubMed ID: 28255348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stimuli-responsive drug delivery systems for head and neck cancer therapy.
    Liang J; Yang B; Zhou X; Han Q; Zou J; Cheng L
    Drug Deliv; 2021 Dec; 28(1):272-284. PubMed ID: 33501883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Smart stimuli-responsive biopolymeric nanomedicines for targeted therapy of solid tumors.
    Fathi M; Abdolahinia ED; Barar J; Omidi Y
    Nanomedicine (Lond); 2020 Sep; 15(22):2171-2200. PubMed ID: 32912045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor Abnormality-Oriented Nanomedicine Design.
    Zhou Q; Xiang J; Qiu N; Wang Y; Piao Y; Shao S; Tang J; Zhou Z; Shen Y
    Chem Rev; 2023 Sep; 123(18):10920-10989. PubMed ID: 37713432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultrasound-mediated nano drug delivery for treating cancer: Fundamental physics to future directions.
    Moradi Kashkooli F; Jakhmola A; Hornsby TK; Tavakkoli JJ; Kolios MC
    J Control Release; 2023 Mar; 355():552-578. PubMed ID: 36773959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicines Targeting the Tumor Microenvironment.
    Tong R; Langer R
    Cancer J; 2015; 21(4):314-21. PubMed ID: 26222084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in hyaluronic acid-based nanomedicines: Preparation and application in cancer therapy.
    Hou X; Zhong D; Chen H; Gu Z; Gong Q; Ma X; Zhang H; Zhu H; Luo K
    Carbohydr Polym; 2022 Sep; 292():119662. PubMed ID: 35725165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimuli-responsive drug delivery systems triggered by intracellular or subcellular microenvironments.
    Sun T; Jiang C
    Adv Drug Deliv Rev; 2023 May; 196():114773. PubMed ID: 36906230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nano-, micro-, and macroscale drug delivery systems for cancer immunotherapy.
    Huang P; Wang X; Liang X; Yang J; Zhang C; Kong D; Wang W
    Acta Biomater; 2019 Feb; 85():1-26. PubMed ID: 30579043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endogenous stimuli-responsive linkers in nanoliposomal systems for cancer drug targeting.
    Faal Maleki M; Jafari A; Mirhadi E; Askarizadeh A; Golichenari B; Hadizadeh F; Jalilzadeh Moghimi SM; Aryan R; Mashreghi M; Jaafari MR
    Int J Pharm; 2019 Dec; 572():118716. PubMed ID: 31705978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems.
    van Elk M; Murphy BP; Eufrásio-da-Silva T; O'Reilly DP; Vermonden T; Hennink WE; Duffy GP; Ruiz-Hernández E
    Int J Pharm; 2016 Dec; 515(1-2):132-164. PubMed ID: 27725268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal clearable nanocarriers: Overcoming the physiological barriers for precise drug delivery and clearance.
    Peng C; Huang Y; Zheng J
    J Control Release; 2020 Jun; 322():64-80. PubMed ID: 32194171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in dual- and multi-responsive nanomedicines for precision cancer therapy.
    Zhang Y; Li J; Pu K
    Biomaterials; 2022 Dec; 291():121906. PubMed ID: 36395660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimuli-Responsive Nanomedicines for Overcoming Cancer Multidrug Resistance.
    Zhou L; Wang H; Li Y
    Theranostics; 2018; 8(4):1059-1074. PubMed ID: 29463999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-Targeted Nanomedicine for Immunotherapy.
    Cabral H; Kinoh H; Kataoka K
    Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Intracellular and Extracellular Microenvironment of Tumor Site: The Trigger of Stimuli-Responsive Drug Delivery Systems.
    Jing X; Hu H; Sun Y; Yu B; Cong H; Shen Y
    Small Methods; 2022 Mar; 6(3):e2101437. PubMed ID: 35048560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimuli-Responsive Nano-Architecture Drug-Delivery Systems to Solid Tumor Micromilieu: Past, Present, and Future Perspectives.
    El-Sawy HS; Al-Abd AM; Ahmed TA; El-Say KM; Torchilin VP
    ACS Nano; 2018 Nov; 12(11):10636-10664. PubMed ID: 30335963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Responsive Role of Nanomedicine in the Tumor Microenvironment and Cancer Drug Resistance.
    Sa P; Sahoo SK; Dilnawaz F
    Curr Med Chem; 2023; 30(29):3335-3355. PubMed ID: 36154585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.